Systemic juvenile idiopathic arthritis

Textbook of Pediatric Rheumatology

Volumn , Issue , 2011, Pages 236-248

  De Benedetti, Fabrizio ^a   Schneider, Rayfel ^b,c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054849206     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6581-4.10014-7     Document Type: Chapter

References (243)

1. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol 2004, 31:390-392.
2. Ogilvie E.M., Fife M.S., Thompson S.D., et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003, 48:3202-3206.
3. De Benedetti F., Meazza C., Vivarelli M., et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003, 48:1398-1407.
4. Barnes M.G., Grom A.A., Thompson S.D., et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:2102-2112.
5. de Jager W., Hoppenreijs E.P., Wulffraat N.M., et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis 2007, 66:589-598.
6. de Benedetti F. Martini: Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?. Arthritis Rheum 2005, 52:687-693.
7. De Benedetti F., Rucci N., Del Fattore A., et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006, 54:3551-3563.
8. Frosch M., Ahlmann M., Vogl T., et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis. Rheum 2009, 60:883-891.
9. Gattorno M., Piccini A., Lasiglie D., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:1505-1515.
10. Behrens E.M., Beukelman T., Gallo L., et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J. Rheumatol 2008, 35:343-348.
11. Schneider R., Lang B.A., Reilly B.J., et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J. Pediatr 1992, 120:200-205.
12. Bywaters E.G., Isdale I.C. The rash of rheumatoid arthritis and Still's disease. Q. J. Med 1956, 25:377-387.
13. Schaller J., Wedgwood R.J. Pruritus associated with the rash of juvenile rheumatoid arthritis. Pediatrics 1970, 45:296-298.
14. Goldenberg J., Ferraz M.B., Pessoa A.P., et al. Symptomatic cardiac involvement in juvenile rheumatoid arthriti. Int. J. Cardiol 1992, 34:57-62.
15. Heyd J., Glaser J. Early occurrence of aortic valve regurgitation in a youth with systemic-onset juvenile rheumatoid arthritis. Am. J. Med 1990, 89:123-124.
16. Athreya B.H., Doughty R.A., Bookspan M., et al. Pulmonary manifestations of juvenile rheumatoid arthritis. A report of eight cases and review. Clin. Chest Med 1980, 1:361-374.
17. Schultz R., Mattila J., Gappa M., et al. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA). Pediatr. Pulmonol 2001, 32:397-402.
18. Schaller J., Beckwith B., Wedgwood R.J. Hepatic involvement in juvenile rheumatoid arthritis. J. Pediatr 1970, 77:203-210.
19. Ohta A., Yamaguchi M., Tsunematsu T., et al. Adult Still's disease: a multicenter survey of Japanese patients. J. Rheumatol 1990, 17:1058-1063.
20. Tabak F., Tanverdi M., Ozaras R., et al. Neutrophilic pleocytosis in cerebrospinal fluid: adult-onset Still's disease. Intern. Med 2003, 42:1039-1041.
21. Avcin T., Silverman E.D., Forte V., et al. Nasal septal perforation: a novel clinical manifestation of systemic juvenile idiopathic arthritis/adult onset Still's disease. J. Rheumatol 2005, 32:2429-2431.
22. Sawhney S., Woo P., Murray K.J. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch. Dis. Child 2001, 85:421-426.
23. Stephan J.L., Kone-Paut I., Galambrun C., et al. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford) 2001, 40:1285-1292.
24. Henter J.I., Home A., Arico M., et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2007, 48:124-131.
25. Ravelli A., Magni-Manzoni S., Pistorio A., et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr 2005, 146:598-604.
26. Ansell B.M. Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis. J. Rheumatol 1999, 26:765-766.
27. Immonen K., Savolainen A., Kautiainen H., et al. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis. J. Rheumatol 2008, 35:907-912.
28. Gottenberg J.E., Merle-Vincent F., Bentaberry F., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003, 48:2019-2024.
29. Okuda Y., Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis. Rheum 2006, 54:2997-3000.
30. Manki A., Nishikomori R., Nakata-Hizume M., et al. Tumor necrosis factor receptor-associated periodic syndrome mimicking systemic juvenile idiopathic arthritis. Allergol. Int 2006, 55:337-341.
31. Wittkowski H., Frosch M., Wulffraat N., et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 2008, 58:3924-3931.
32. Oen K., Reed M., Malleson P.N., et al. Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J. Rheumatol 2003, 30:832-840.
33. Quartier P., Taupin P., Bourdeaut F., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48:1093-1101.
34. Kimura Y., Pinho P., Walco G., et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J. Rheumatol 2005, 32:935-942.
35. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
36. Lequerre T., Quartier P., Rosellini D., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis 2008, 67:302-308.
37. Woo P., Southwood T.R., Prieur A.M., et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritisy. Arthritis Rheum 2000, 43:1849-1857.
38. Silverman E.D., Cawkwell G.D., Lovell D.J., et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Groupy, J. Rheumatol 1994, 21:2353-2358.
39. Lehman T.J., Schechter S.J., Sundel R.P., et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J. Pediatr 2004, 145:856-857.
40. Abinun M., Flood T.J., Cant A.J., et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007). Mol. Immunol 2009, 47:46-51.
41. Brinkman D.M., de Kleer I.M., ten Cate R., et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 2007, 56:2410-2421.
42. Spiegel L.R., Schneider R., Lang B.A., et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000, 43:2402-2409.
43. Modesto C., Woo P., Garcia-Consuegra J., et al. Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin. Exp. Rheumatol 2001, 19:211-217.
44. Sandborg C., Holmes T.H., Lee T., et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J. Rheumatol 2006, 33:2322-2329.
45. Still G.F. On a form of chronic joint disease in children. Med. Chir. Trans 1897, 80:47-59.
46. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001,. J. Rheumatol 2004, 31:390-392.
47. Berntson L., Andersson Gare B., Fasth A., et al. Incidence of juvenile idiopathic arthritis in the Nordic countries: a population based study with special reference to the validity of the ILAR and EULAR criteria. J. Rheumatol 2003, 30:2275-2282.
48. Danner S., Sordet C., Terzic J., et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J. Rheumatol 2006, 33:1377-1381.
49. Huemer C., Huemer M., Dorner T., et al. Incidence of pediatric rheumatic diseases in a regional population in Austria. J. Rheumatol 2001, 28:2116-2119.
50. Moe N., Rygg M. Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin. Exp. Rheumatol 1998, 16:99-101.
51. Gare B.A., Fasth A. Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics 1992, 90:950-958.
52. Fujikawa S., Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children,. Acta. Paediatr. Jpn 1997, 39:242-244.
53. Seth V., Kabra S.K., Semwal O.P., et al. Clinico-immunological profile in juvenile rheumatoid arthritis-an Indian experience. Indian J. Pediatr 1996, 63:293-300.
54. Feldman B.M., Birdi N., Boone J.E., et al. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J. Pediatr 1996, 129:513-518.
55. Lindsley C.B. Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 1987, 30:838-839.
56. Sullivan D.B., Cassidy J.T., Petty R.E. Pathogenic implications of age of onset in juvenile rheumatoid arthritis. Arthritis Rheum 1975, 18:251-255.
57. Uziel Y., Pomeranz A., Brik R., et al. Seasonal variation in systemic onset juvenile rheumatoid arthritis in Israel. J. Rheumatol 1999, 26:1187-1189.
58. Ogilvie E.M., Fife M.S., Thompson S.D., et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families,. Arthritis Rheum 2003, 48:3202-3206.
59. Moroldo M.B., Chaudhari M., Shear E., et al. Juvenile rheumatoid arthritis affected sibpairs: extent of clinical phenotype concordance. Arthritis Rheum 2004, 50:1928-1934.
60. Thomson W., Barrett J.H., Donn R., et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford) 2002, 41:1183-1189.
61. Fishman D., Faulds G., Jeffery R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis,. J. Clin. Invest 1998, 102:1369-1376.
62. Date Y., Seki N., Kamizono S., et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNF alpha gene and HLA genes. Arthritis Rheum 1999, 42:2577-2582.
63. De Benedetti F., Meazza C., Vivarelli M., et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis,. Arthritis Rheum 2003, 48:1398-1407.
64. Donn R., Alourfi Z., De Benedetti F., et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002, 46:2402-2409.
65. Donn R.P., Shelley E., Ollier W.E., et al. A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis,. Arthritis Rheum 2001, 44:1782-1785.
66. Stock C.J., Ogilvie E.M., Samuel J.M., Fife M., et al. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes. Immun 2008, 9:349-357.
67. Barnes M.G., Grom A.A., Thompson S.D., et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis,. Arthritis Rheum 2009, 60:2102-2112.
68. Allantaz F., Chaussabel D., Stichweh D., et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med 2007, 204:2131-2144.
69. Ishikawa S., Mima T., Aoki C., et al. Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis. Ann. Rheum. Dis 2009, 68:264-272.
70. Ogilvie E.M., Khan A., Hubank M., et al. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56:1954-1965.
71. Pascual V., Allantaz F., Arce E., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med 2005, 201:1479-1486.
72. Meazza C., Travaglino P., Pignatti P., et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002, 46:232-237.
73. De Benedetti F., Massa M., Pignatti P., et al. Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J. Rheumatol 1995, 22:1581-1585.
74. De Benedetti F., Pignatti P., Bernasconi S., et al. Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis: relation to onset types, disease activity, and synovial fluid leukocytes. J. Rheumatol 1999, 26:425-431.
75. Mangge H., Kenzian H., Gallistl S., et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995, 38:211-220.
76. de Jager W., Hoppenreijs E.P., Wulffraat N.M., et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study,. Ann. Rheum. Dis 2007, 66:589-598.
77. Lotito A.P., Campa A., Silva C.A., et al. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J. Rheumatol 2007, 34:823-830.
78. Rooney M., David J., Symons J., et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br. J. Rheumatol 1995, 34:454-460.
79. van den Ham H.J., de Jager W., Bijlsma J.W., et al. Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford) 2009, 48:899-905.
80. de Benedetti F., Pignatti P., Massa M., et al. Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br. J. Rheumatol 1997, 36:581-588.
81. Muzaffer M.A., Dayer J.M., Feldman B.M., et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J. Rheumatol 2002, 29:1071-1078.
82. Prieur A.M., Roux-Lombard P., Dayer J.M. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev. Rhum. Engl. Ed 1996, 63:163-170.
83. de Benedetti F., Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?. Arthritis Rheum 2005, 52:687-693.
84. de Benedetti F., Massa M., Robbioni P., et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158-1163.
85. De Benedetti F., Pignatti P., Gerloni V., et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J. Rheumatol 1997, 24:1403-1409.
86. Lepore L., Pennesi M., Saletta S., et al. Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin. Exp. Rheumatol 1994, 12:561-565.
87. Pignatti P., Vivarelli M., Meazza C., et al. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J. Rheumatol 2001, 28:1670-1676.
88. Alonzi T., Fattori E., Lazzaro D., et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med 1998, 187:461-468.
89. De Benedetti F., Alonzi T., Moretta A., et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation,. J. Clin. Invest 1997, 99:643-650.
90. De Benedetti F., Rucci N., Del Fattore A., et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system,. Arthritis Rheum 2006, 54:3551-3563.
91. Cazzola M., Ponchio L., de Benedetti F., et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996, 87:4824-4830.
92. Frosch M., Ahlmann M., Vogl T., et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis,. Arthritis Rheum 2009, 60:883-891.
93. Ogilvie E.M., Khan A., Hubank M., et al. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56:1954-1965.
94. Barnes M.G., Grom A.A., Thompson S.D., et al. Subtype-specific perpheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:2102-2112.
95. Gattorno M., Piccini A., Lasiglie D., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis,. Arthritis Rheum 2008, 58:1505-1515.
96. Frosch M., Vogl T., Seeliger S., et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003, 48:2622-2626.
97. Viemann D., Strey A., Janning A., et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005, 105:2955-2962.
98. Vogl T., Tenbrock K., Ludwig S., et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med 2007, 13:1042-1049.
99. Behrens E.M., Beukelman T., Gallo L., et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR),. J. Rheumatol 2008, 35:343-348.
100. Schneider R., Lang B.A., Reilly B.J., et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis,. J. Pediatr 1992, 120:200-205.
101. Miller M.L., Levinson L., Pachman L.M., et al. Abnormal muscle MRI in a patient with systemic juvenile arthritis. Pediatr. Radiol 1995, 25(suppl. 1):S107-S108.
102. Bywaters E.G., Isdale I.C. The rash of rheumatoid arthritis and Still's disease,. Q. J. Med 1956, 25:377-387.
103. Schaller J., Wedgwood R.J. Pruritus associated with the rash of juvenile rheumatoid arthritis. Pediatrics 1970, 45:296-298.
104. Prendiville J.S., Tucker L.B., Cabral D.A., et al. A pruritic linear urticarial rash, fever, and systemic inflammatory disease in five adolescents: adult-onset still disease or systemic juvenile idiopathic arthritis sine arthritis?. Pediatr. Dermatol 2004, 21:580-588.
105. Alukal M.K., Costello P.B., Green F.A. Cardiac tamponade in systemic juvenile rheumatoid arthritis requiring emergency pericardiectomy. J. Rheumatol 1984, 11:222-225.
106. Goldenberg J., Ferraz M.B., Pessoa A.P., et al. Symptomatic cardiac involvement in juvenile rheumatoid arthriti,. Int. J. Cardiol 1992, 34:57-62.
107. Lietman P.S., Bywaters E.G. Pericarditis in Juvenile Rheumatoid Arthritis. Pediatrics 1963, 32:855-860.
108. Bernstein B., Takahashi M., Hanson V. Cardiac involvement in juvenile rheumatoid arthritis. J. Pediatr 1974, 85:313-317.
109. Scharf J., Levy J., Benderly A., et al. Pericardial tamponade in juvenile rheumatoid arthritis. Arthritis Rheum 1976, 19:760-762.
110. Brewer E. Jr., Juvenile rheumatoid arthritis-cardiac involvement. Arthritis Rheum 1977, 20(Suppl. 2):231-236.
111. Svantesson H., Bjorkhem G., Elborgh R. Cardiac involvement in juvenile rheumatoid arthritis. A follow-up study,. Acta. Paediatr. Scand 1983, 72:345-350.
112. Majeed H.A., Kvasnicka J. Juvenile rheumatoid arthritis with cardiac tamponade. Ann. Rheum. Dis 1978, 37:273-276.
113. Yancey C.L., Doughty R.A., Cohlan B.A., et al. Pericarditis and cardiac tamponade in juvenile rheumatoid arthritis. Pediatrics 1981, 68:369-373.
114. Miller J.J., French J.W. Myocarditis in juvenile rheumatoid arthritis. Am. J. Dis Child 1977, 131:205-209.
115. Oguz D., Ocal B., Ertan U., et al. Left ventricular diastolic functions in juvenile rheumatoid arthritis. Pediatr. Cardiol 2000, 21:374-377.
116. Kramer P.H., Imboden J.B., Waldman F.M., et al. Severe aortic insufficiency in juvenile chronic arthritis. Am. J. Med 1983, 74:1088-1091.
117. Heyd J., Glaser J. Early occurrence of aortic valve regurgitation in a youth with systemic-onset juvenile rheumatoid arthritis,. Am. J. Med 1990, 89:123-124.
118. Brinkman G.L., Chaikof L. Rheumatoid lung disease: report of a case which developed in childhood. Am. Rev. Respir. Dis 1959, 80:732-737.
119. Athreya B.H., Doughty R.A., Bookspan M., et al. Pulmonary manifestations of juvenile rheumatoid arthritis. A report of eight cases and review,. Clin. Chest Med 1980, 1:361-374.
120. Jordan J.D., Snyder C.H. Rheumatoid Disease of the Lung and Cor Pulmonale. Observations in a Child. Am. J. Dis. Child 1964, 108:174-180.
121. Lovell D., Lindsley C., Langston C. Lymphoid interstitial pneumonia in juvenile rheumatoid arthritis. J. Pediatr 1984, 105:947-950.
122. Noyes B.E., Albers G.M., deMello D.E., et al. Early onset of pulmonary parenchymal disease associated with juvenile rheumatoid arthritis. Pediatr. Pulmonol 1997, 24:444-446.
123. Uziel Y., Hen B., Cordoba M., et al. Lymphocytic interstitial pneumonitis preceding polyarticular juvenile rheumatoid arthritis. Clin. Exp. Rheumatol 1998, 16:617-619.
124. Wagener J.S., Taussig L.M., DeBenedetti C., et al. Pulmonary function in juvenile rheumatoid arthriti. J. Pediatr 1981, 99:108-110.
125. Braidy J.F., Poulson J.M. Diaphragmatic weakness and myositis associated with systemic juvenile rheumatoid arthritis. Can. Med. Assoc. J 1984, 130:47-49.
126. Knook L.M., de Kleer I.M., van der Ent C.K., et al. Lung function abnormalities and respiratory muscle weakness in children with juvenile chronic arthritis. Eur. Respir. J 1999, 14:529-533.
127. Padeh S., Laxer R.M., Silver M.M., et al. Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritis. Arthritis Rheum 1991, 34:1575-1579.
128. Schultz R., Mattila J., Gappa M., et al. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA),. Pediatr. Pulmonol 2001, 32:397-402.
129. Ramanan A.V., Wynn R.F., Kelsey A., et al. Systemic juvenile idiopathic arthritis, Kikuchi's disease and haemophagocytic lymphohistiocytosis-is there a link? Case report and literature review. Rheumatology (Oxford) 2003, 42:596-598.
130. Schaller J., Beckwith B., Wedgwood R.J. Hepatic involvement in juvenile rheumatoid arthritis,. J. Pediatr 1970, 77:203-210.
131. Boone J.E. Hepatic disease and mortality in juvenile rheumatoid arthritis. Arthritis Rheum 1977, 257(suppl. 20).
132. Jacobs J.C. JRA and hyperphosphataemis. J. Pediatr 1985, 107:828-829.
133. Lockitch G., Pudek M.R., Halstead A.C. Isolated elevation of serum alkaline phosphatase. J. Pediatr 1984, 105:773-775.
134. Rennebohm R.M., Heubi J.E., Daugherty C.C., et al. Reye syndrome in children receiving salicylate therapy for connective tissue diseas. J. Pediatr 1985, 107:877-880.
135. Blockmans D.E., Knockaert D.C., Bobbaers H.J. Still's disease can cause neutrophilic meningitis. Neurology 2000, 54:1203-1205.
136. Garrote F.J., Marco J., Obeso G., et al. Aseptic meningitis and focal central nervous system involvement in a case of adult onset Still's disease. J. Rheumatol 1993, 20:765-767.
137. Ohta A., Yamaguchi M., Tsunematsu T., et al. Adult Still's disease: a multicenter survey of Japanese patients,. J. Rheumatol 1990, 17:1058-1063.
138. Tabak F., Tanverdi M., Ozaras R., et al. Neutrophilic pleocytosis in cerebrospinal fluid: adult-onset Still's disease,. Intern. Med 2003, 42:1039-1041.
139. Schneider R., Silverman E.D., Feldman B.M., et al. Acute fatal neurologic events in severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43(suppl.). s119.
140. Hadchouel M., Prieur A.M., Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J. Pediatr 1985, 106:561-566.
141. Arroyo I.L., Barron K.S., Brewer E.J. Spinal cord compression by epidural lipomatosis in juvenile rheumatoid arthritis. Arthritis Rheum 1988, 31:447-451.
142. Avcin T., Silverman E.D., Forte V., et al. Nasal septal perforation: a novel clinical manifestation of systemic juvenile idiopathic arthritis/adult onset Still's disease,. J. Rheumatol 2005, 32:2429-2431.
143. Sawhney S., Woo P., Murray K.J. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders,. Arch. Dis. Child 2001, 85:421-426.
144. Avcin T., Tse S.M., Schneider R., et al. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J. Pediatr 2006, 148:683-686.
145. Pringe A., Trail L., Ruperto N., et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?. Lupus 2007, 16:587-592.
146. Stephan J.L., Kone-Paut I., Galambrun C., et al. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients,. Rheumatology (Oxford.) 2001, 40:1285-1292.
147. Aellen P., Raccaud O., Waldburger M., et al. Still's disease in adults with disseminated intravascular coagulation. Schweiz. Rundsch. Med. Prax 1991, 80:376-378.
148. Grom A.A., Villanueva J., Lee S., et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr 2003, 142:292-296.
149. Barash J., Cooper M., Tauber Z. Hepatic, cutaneous and hematologic manifestations in juvenile chronic arthritis. Clin. Exp. Rheumatol 1991, 9:541-543.
150. Jacobs J.C., Gorin L.J., Hanissian A.S., et al. Consumption coagulopathy after gold therapy for JRA. J. Pediatr 1984, 105:674-675.
151. Manners P.J., Ansell B.M. Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis. Pediatrics 1986, 77:99-103.
152. Eraso R., Gedalia A., Espinoza L.R. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J. Rheumatol 2002, 29:1104-1105.
153. Ramanan A.V., Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J. Rheumatol 2003, 30:401-403.
154. Ravelli A., Caria M.C., Buratti S., et al. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J. Rheumatol 2001, 28:865-867.
155. Silverman E.D., Miller J.J., Bernstein B., Shafai T. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J. Pediatr 1983, 103:872-876.
156. Ravelli A. Macrophage activation syndrome. Curr. Opin. Rheumatol 2002, 14:548-552.
157. Behrens E.M., Beukelman T., Paessler M., Cron R.Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol 2007, 34:1133-1138.
158. Henter J.I., Horne A., Arico M., et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2007, 48:124-131.
159. Ravelli A., Magni-Manzoni S., Pistorio A., et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr 2005, 146:598-604.
160. Emmenegger U., Frey U., Reimers A., et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am. J. Hematol 2001, 68:4-10.
161. Mouy R., Stephan J.L., Pillet P., et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J. Pediatr 1996, 129:750-754.
162. Quesnel B., Catteau B., Aznar V., et al. Successful treatment of juvenile rheumatoid arthritis associated heamophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF. Br. J. Haematol 1997, 97:508-510.
163. Ravelli A., De Benedetti F., Viola S., Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J. Pediatr 1996, 128:275-278.
164. Calabro J.J. Amyloidosis and juvenile rheumatoid arthritis. J. Pediatr 1969, 75:521.
165. Schnitzer T.J., Ansell B.M. Amyloidosis in juvenile chronic polyarthritis. Arthritis. Rheum 1977, 20(suppl. 2):245-252.
166. Ozdogan H., Kasapcopur O., Dede H., et al. Juvenile chronic arthritis in a Turkish population. Clin. Exp. Rheumatol 1991, 9:431-435.
167. Ansell B.M. Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis,. J. Rheumatol 1999, 26:765-766.
168. David J., Vouyiouka O., Ansell B.M., et al. Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin. Exp. Rheumatol 1993, 11:85-90.
169. Savolainen H.A., Isomaki H.A. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J. Rheumatol 1993, 20:1201-1203.
170. Immonen K., Savolainen H.A., Hakala M. Why can we no longer find juvenile idiopathic arthritis-associated amyloidosis in childhood or in adolescence in Finland. Scand. J. Rheumatol 2007, 36:402-403.
171. Burman S.J., Hall P.J., Bedford P.A., et al. HLA antigen frequencies among patients with juvenile chronic arthritis and amyloidosis: a brief report. Clin. Exp. Rheumatol 1986, 4:261-263.
172. Woo P., O'Brien J., Robson M., et al. A genetic marker for systemic amyloidosis in juvenile arthritis,. Lancet 1987, 2:767-769.
173. Hawkins P.N., Richardson S., Vigushin D.M., et al. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum 1993, 36:842-851.
174. Bywaters E.G. Deaths in juvenile chronic polyarthritis. Arthritis Rheum 1977, (20 (suppl). 256.
175. Immonen K., Savolainen A., Kautiainen H., et al. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis,. J. Rheumatol 2008, 35:907-912.
176. Gillmore J.D., Lovat L.B., Persey M.R., et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001, 358:24-29.
177. Gottenberg J.E., Merle-Vincent F., Bentaberry F., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy,. Arthritis Rheum 2003, 48:2019-2024.
178. Okuda Y., Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis,. Arthritis Rheum 2006, 54:2997-3000.
179. Miller L.C., Sisson B.A., Tucker L.B., et al. Prolonged fevers of unknown origin in children: patterns of presentation and outcome. J. Pediatr 1996, 129:419-423.
180. Manki A., Nishikomori R., Nakata-Hizume M., et al. Tumor necrosis factor receptor-associated periodic syndrome mimicking systemic juvenile idiopathic arthritis,. Allergol. Int 2006, 55:337-341.
181. Sievers K., Ahvonen P., Aho K., et al. Serological Patterns in Juvenile Rheumatoid Arthritis. Rheumatism 1963, 19:88-93.
182. Aptekar R.G., Decker J.L., Bujak J.S., et al. Adult onset juvenile rheumatoid arthritis. Arthritis Rheum 1973, 16:715-718.
183. Bywaters E.G. Still's disease in the adult. Ann. Rheum. Dis 1971, 30:121-133.
184. Cush J.J., Medsger T.A., Christy W.C., Herbert D.C., Cooperstein L.A. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987, 30:186-194.
185. Roberts-Thomson P.J., Southwood T.R., Moore B.W., et al. Adult onset Still's disease or coxsackie polyarthritis?. Aust. N. Z. J. Med 1986, 16:509-511.
186. Fardet L., Coppo P., Kettaneh A., et al. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum 2008, 58:1521-1527.
187. Fautrel B., Le Moel G., Saint-Marcoux B., et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J. Rheumatol 2001, 28:322-329.
188. Wang Z., Wang Y., Wang J., et al. Early diagnostic value of low percentage of glycosylated ferritin in secondary hemophagocytic lymphohistiocytosis. Int. J. Hematol 2009, 90:501-505.
189. Bjorkengren A.G., Pathria M.N., Sartoris D.J., et al. Carpal alterations in adult-onset Still disease, juvenile chronic arthritis, and adult-onset rheumatoid arthritis: comparative study. Radiology 1987, 165:545-548.
190. Sherry D.D., Kredich D.W. Transient thrombocytopenia in systemic onset juvenile rheumatoid arthritis. Pediatrics 1985, 76:600-603.
191. Ewer A.K., Darbyshire P.J., Southwood T.R. Systemic-onset juvenile chronic arthritis and bone marrow hypoplasis. Br. J. Rheumatol 1993, 32:78-80.
192. Rubin R.N., Walker B.K., Ballas S.K., et al. Erythroid aplasia in juvenile rheumatoid arthritis. Am. J. Dis. Child 1978, 132:760-762.
193. Miller J.J., Hsu Y.P., Moss R., et al. The immunologic and clinical associations of the split products of C3 in plasma in juvenile rheumatoid arthritis,. Arthritis Rheum 1979, 22:502-507.
194. Wittkowski H., Frosch M., Wulffraat N., et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 2008, 58:3924-3931.
195. Oen K., Reed M., Malleson P.N., et al. Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis,. J. Rheumatol 2003, 30:832-840.
196. Lang B.A., Schneider R., Reilly B.J., et al. Radiologic features of systemic onset juvenile rheumatoid arthritis. J. Rheumatol 1995, 22:168-173.
197. Breit W., Frosch M., Meyer U., et al. A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis,. J. Rheumatol 2000, 27:2696-2702.
198. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl J. Med 2000, 342:763-769.
199. Lovell D.J., Giannini E.H., Reiff A., et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003, 48:218-226.
200. Horneff G., Schmeling H., Biedermann T., et al. The German etanercept registry for treatment of juvenile idiopathic arthritis,. Ann. Rheum. Dis 2004, 63:1638-1644.
201. Prince F.H., Twilt M., ten Cate R., et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann. Rheum. Dis 2009, 68:635-641.
202. Quartier P., Taupin P., Bourdeaut F., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type,. Arthritis Rheum 2003, 48:1093-1101.
203. Kimura Y., Pinho P., Walco G., et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis,. J. Rheumatol 2005, 32:935-942.
204. Lovell D.J., Ruperto N., Goodman S., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med 2008, 359:810-820.
205. Ruperto N., Lovell D.J., Cuttica R., et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis,. Arthritis Rheum 2007, 56:3096-3106.
206. Russo R.A., Katsicas M.M. Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents. J. Rheumatol 2009, 36:1078-1082.
207. Woo P., Wilkinson N., Prieur A.M., et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther 2005, 7:R1281-R1288.
208. Yokota S., Miyamae T., Imagawa T., et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:818-825.
209. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial,. Lancet 2008, 371:998-1006.
210. Verbsky J.W., White A.J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritisy. J. Rheumatol 2004, 31:2071-2075.
211. Zeft A., Hollister R., LaFleur B., et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J. Clin. Rheumatol 2009, 15:161-164.
212. Lequerre T., Quartier P., Rosellini D., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France,. Ann. Rheum. Dis 2008, 67:302-308.
213. Ohlsson V., Baildam E., Foster H., et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 2008, 47:555-556.
214. Ruperto N., Quartier P., Wulffraat N., et al. ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody has a beneficial effect in children with systemic juvenile idiopathic arthritis (abstract). Arthritis Rheum 2008, 58(suppl.). s942.
215. Woo P., Southwood T.R., Prieur A.M., et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritisy. Arthritis Rheum 2000, 43:1849-1857.
216. Groothoff J.W., van Leeuwen E.F. High dose intravenous gammaglobulin in chronic systemic juvenile arthritis. Br. Med. J. (Clin. Res. Ed.) 1988, 296:1362-1363.
217. Prieur A.M., Adleff A., Debre M., et al. High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patientsy. Clin. Exp. Rheumatol 1990, 8:603-608.
218. Silverman E.D., Laxer R.M., Greenwald M., et al. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritisy. Arthritis Rheum 1990, 33:1015-1022.
219. Uziel Y., Laxer R.M., Schneider R., et al. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J. Rheumatol 1996, 23:910-918.
220. Silverman E.D., Cawkwell G.D., Lovell D.J., et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Groupy. J. Rheumatol 1994, 21:2353-2358.
221. Gerloni V., Cimaz R., Gattinara M., et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis: results of a 10-year prospective study. Rheumatology (Oxford) 2001, 40:907-913.
222. Ruperto N., Ravelli A., Castell E., et al. Cyclosporine A in juvenile idiopathic arthritis: results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin. Exp. Rheumatol 2006, 24:599-605.
223. Lehman T.J., Schechter S.J., Sundel R.P., et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study,. J. Pediatr 2004, 145:856-857.
224. Garcia-Carrasco M., Fuentes-Alexandro S., Escarcega R.O., et al. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine 2007, 74:500-503.
225. Abinun M., Flood T.J., Cant A.J., et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007). Mol. Immunol. 2009, 47:46-51.
226. Brinkman D.M., de Kleer I.M., ten Cate R., et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial,. Arthritis Rheum 2007, 56:2410-2421.
227. Calabro J.J., Holgerson W.B., Sonpal G.M., et al. Juvenile rheumatoid arthritis: a general review and report of 100 patients observed for 15 years. Semin. Arthritis Rheum 1976, 5:257-298.
228. Fantini F., Gerloni V., Gattinara M., et al. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J. Rheumatol 2003, 30:579-584.
229. Lomater C., Gerloni V., Gattinara M., et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol 2000, 27:491-496.
230. Singh-Grewal D., Schneider R., Bayer N., et al. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006, 54:1595-1601.
231. Spiegel L.R., Schneider R., Lang B.A., et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000, 43:2402-2409.
232. Lin S.J., Huang J.L., Chao H.C., et al. A follow-up study of systemic-onset juvenile rheumatoid arthritis in children,. Acta. Paediatr, Taiwan 1999, 40:176-181.
233. van der Net J., Kuis W., Prakken A.B., et al. Correlates of disablement in systemic onset juvenile chronic arthritis: a cross sectional study. Scand. J. Rheumatol 1997, 26:188-196.
234. Wallace C.A., Levinson J.E. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum. Dis. Clin. North Am 1991, 17:891-905.
235. Minden K., Kiessling U., Listing J., et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J. Rheumatol 2000, 27:2256-2263.
236. Oen K., Malleson P.N., Cabral D.A., et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J. Rheumatol 1989, 29:1099-2002.
237. Wallace C.A., Huang B., Bandeira M., et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:3554-3562.
238. Modesto C., Woo P., Garcia-Consuegra J., et al. Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis,. Clin. Exp. Rheumatol 2001, 19:211-217.
239. Sandborg C., Holmes T.H., Lee T., et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J. Rheumatol 2006, 33:2322-2329.
240. Bloom B.J., Alario A.J., Miller L.C. Persistent elevation of fibrin D-dimer predicts longterm outcome in systemic juvenile idiopathic arthritis. J. Rheumatol 2009, 36:422-426.
241. Oen K., Malleson P.N., Cabral D.A., et al. Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J. Rheumatol 2003, 30:585-593.
242. Baum J., Gutowska G. Death in juvenile rhuematoid arthritis. Arthritis Rheum 1977, 20(suppl):253-255.
243. Bernstein B. Death in juvenile rheumatoid arthritis. Arthritis Rheum 1977, 20(suppl):256.